



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 06.01.2024

To,
The DCS- Listing,
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub.: Filing of Reports for the quarter ended on 31.12.2023

Dear Sir,

With reference to various conditions stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other regulation required to be complied by the listed Companies, we are enclosing herewith the Compliance Certificate under Regulation 74(5) for the quarter ended 31st December, 2023

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172



01 January 2024

To,
BERYL DRUGS LIMITED
133, GROUND FLOOR
KANCHAN BAGH
MADHYA PRADESH
INDORE 452001

Subject: Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and participants) Regulations, 2018.

Dear Sir/Madam,

In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 31st December, 2023, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed.

We hereby also confirm that the security certificates received for dematerialisation have been Mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in register of members as registered owner within 15 days.

We request you to kindly take note of the above in your records.

Thanking you,

Yours faithfully,
For **Adroit Corporate Services Pvt. Ltd.**



Authorized Signatory.